Form D · Biotechnology
iBio, Inc.
San Diego, CA · CIK 0001420720
Offering snapshot reported Jan 22, 2026 · SEC filing
- Reported sold
- $26M Offering amount: $26M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Jan 8, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 22, 2026 | Initial | $25,985,431 | No comparison | 7 | SEC filing |
| May 7, 2025 | Initial | $11,084,569 | No comparison | 5 | SEC filing |
| Apr 4, 2024 | Initial | $15,068,745 | No comparison | 8 | SEC filing |
| Aug 15, 2023 | Initial | $0 | No comparison | 1 | SEC filing |
| Feb 3, 2016 | Initial | $2,177,000 | No comparison | 1 | SEC filing |
| Nov 10, 2010 | Initial | $7,065,000 | No comparison | 52 | SEC filing |
| Sep 23, 2009 | Initial | $3,000,000 | No comparison | 26 | SEC filing |
| Sep 2, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- $1.56M (estimated)
- Finders' fees
- $0
- Form D file number
- 021-570848
Does not include the proceeds to be received upon the cash exercise of pre-funded warrants issued in the private placement at an exercise price of $0.001 per share.
The total sales commission will be divided among the three placement agents as follows: 75% to Leerink Partners LLC, 12.5% to LifeSci Capital LLC and 12.5% to Oppenheimer & Co. Inc.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Leerink Partners LLC | 000039011 | |
| LifeSci Capital LLC | 000168404 | |
| Oppenheimer & Co. Inc. | 000000249 |
Source: Form D, filed Jan 22, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Arkowitz | Director |
| Linda Armstrong | Director |
| Marc Banjak | Executive |
| Pamela Bassett | Director |
| Martin A. Brenner | Director, Executive |
| Glenn Chang | Director |
| William Clark | Director |
| Felipe Duran | Executive |
| Arthur Elliott | Director |
| Robert Erwin | Executive |
| Seymour Flug | Director |
| Mark Giannone | Executive |
| James Hill | Director |
| Robert Kay | Executive |
| Alexandra Kropotova | Director |
| Alexandra Kroptova | Director |
| Frederick Larcombe | Executive |
| John D Mckey | Director |
| John Mc Key | Director |
| Antonio Parada | Director |
| Philip Russell | Director |
| Terence Ryan | Executive |
| Geoffrey Schild | Executive |
| Evert Schimmelpennink | Director |
| Gary Sende | Director |
| Gary Sender | Director |
| Evert Shimmelpennink | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
11750 Sorrento Valley Road, Suite 200
San Diego, CA, 92121
San Diego, CA, 92121